Skip to main content

Table 2 Mean change from baseline in kidney function and Calcium/Phosphorus and the results of the test of the fixed effects by the linear mixed effect model analyses

From: Risedronate therapy in patients with mild-to-moderate chronic kidney disease with osteoporosis: post-hoc analysis of data from the risedronate phase III clinical trials

  eGFR (mL/min/1.73 m2)
90 60 to < 90 30 to < 60
N Mean SD N Mean SD N Mean SD
eGFR (mL/min/1.73 m2) Baseline 99 99.19 9.56 525 72.12 7.98 228 50.74 6.54
12 weeks 94 91.84 15.90 498 70.77 10.92 209 54.43 10.43
24 weeks 89 88.89 12.24 482 70.74 11.26 201 54.64 10.41
36 weeks 86 91.22 13.91 455 71.75 11.65 184 55.54 10.59
48 weeks 84 93.04 14.08 441 72.11 11.95 177 55.06 11.48
  subgroup P < 0.0001
time P < 0.0001
interaction of the subgroup and time P < 0.0001
Creatinine (mg/dL) Baseline 99 0.48 0.05 525 0.64 0.07 228 0.86 0.12
12 weeks 94 0.53 0.09 498 0.65 0.10 209 0.82 0.16
24 weeks 89 0.54 0.08 482 0.65 0.10 201 0.82 0.16
36 weeks 86 0.53 0.09 455 0.65 0.10 184 0.81 0.15
48 weeks 84 0.52 0.08 441 0.64 0.11 177 0.82 0.17
  subgroup P < 0.0001
time P = 0.0178
interaction of the subgroup and time P < 0.0001
Calcium (mg/dL) Baseline 99 9.15 0.37 525 9.08 0.41 228 9.05 0.40
12 weeks 83 9.10 0.39 387 9.10 0.38 115 9.07 0.41
24 weeks 88 9.13 0.36 481 9.12 0.41 198 9.07 0.40
36 weeks 79 9.11 0.40 356 9.17 0.41 111 9.21 0.37
48 weeks 83 9.14 0.35 441 9.13 0.41 182 9.09 0.44
  subgroup P = 0.4597
time P < 0.0001
interaction of the subgroup and time P = 0.1129
Phosphorus (mg/dL) Baseline 26 3.52 0.34 187 3.36 0.47 146 3.43 0.52
12 weeks 14 3.48 0.43 59 3.29 0.49 36 3.36 0.45
24 weeks 22 3.28 0.46 162 3.22 0.55 119 3.31 0.48
36 weeks 14 3.14 0.36 51 3.14 0.48 34 3.31 0.60
48 weeks 20 3.44 0.45 146 3.32 0.48 109 3.35 0.51
  subgroup P = 0.0888
time P < 0.0001
interaction of the subgroup and time P = 0.1041
  1. The linear mixed models included subgroup, time, and interaction of subgroup and time as fixed effects, and the subjects as a random effect